Solubilization of vorinostat by cyclodextrins

Journal of Clinical Pharmacy and Therapeutics

Volumn 35, Issue 5, 2010, Pages 521-526

  Cai, Y Y ^a   Yap, C W ^a   Wang, Z ^a   Ho, P C ^a   Chan, S Y ^a   Ng, K Y ^a   Ge, Z G ^b   Lin, H S ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b PEKING UNIVERSITY   (China)

Author keywords

cyclodextrin; inclusion complex; molecular simulation; phase solubility; vorinostat

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALPHA CYCLODEXTRIN; CYCLODEXTRIN; GAMMA CYCLODEXTRIN; VORINOSTAT;

ARTICLE; DRUG SOLUBILITY; DRUG STRUCTURE; SIMULATION;

ABSORPTION; ADMINISTRATION, ORAL; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CYCLODEXTRINS; EXCIPIENTS; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; INFUSIONS, INTRAVENOUS; MODELS, MOLECULAR; PHYSICOCHEMICAL PHENOMENA; SOLUBILITY;

EID: 77956624263     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01095.x     Document Type: Article

References (16)

1. Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nature Biotechnology, 25, 84 90.
2. Choo QY, Ho PC, Lin HS (2008) Histone deacetylase inhibitors: new hope for rheumatoid arthritis? Current Pharmaceutical Design, 14, 803 820.
3. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery, 5, 769 784.
4. FDA (2006) Available at: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=Search.Label-ApprovalHistory#apphist (accessed 08 December 2008).
5. ClinicalTrials.gov (2009). A Service of the US National Institute of Health. Available at: http://www.clinicaltrials.gov. (accessed 04 April 2009).
6. Lin HS, Hu CY, Chan HY et al. (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. British Journal of Pharmacology, 150, 862 872.
7. Hockly E, Richon VM, Woodman B et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America, 100, 2041 2046.
8. Kelly WK, Richon VM, O'Connor O et al. (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clinical Cancer Research, 9, 3578 3588.
9. Davis ME, Brewster ME (2004) Cyclodextrin-based pharmaceutics: past, present and future. Nature Reviews Drug Discovery, 3, 1023 1035.
10. Willems L, van der Geest R, de Beule K (2001) Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. Journal of Clinical Pharmacy and Therapeutics, 26, 159 169.
11. Lin HS, Chean CS, Ng YY, Chan SY, Ho PC (2000) 2-hydroxypropyl-beta- cyclodextrin increases aqueous solubility and photostability of all-trans-retinoic acid. Journal of Clinical Pharmacy and Therpeutics, 25, 265 269.
12. Higuchi T, Connors KA (1965) Phase-solubility techniques. Advances in Analytical Chemical Instruments, 4, 117 212.
13. Mura P, Bettinetti G, Melani F, Manderioli A (1995) Interaction between naproxen and chemically modified beta-cyclodextrins in the liquid and solid state. European Journal of Pharmaceutical Sciences, 3, 347 355.
14. Brewster ME, Loftsson T (2007) Cyclodextrins as pharmaceutical solubilizers. Advanced Drug Delivery Reviews, 59, 645 666.
15. Stella VJ, Rao VM, Zannou EA, Zia VV (1999) Mechanisms of drug release from cyclodextrin complexes. Advanced Drug Delivery Reviews, 36, 3 16.
16. Kelly WK, O'Connor OA, Krug LM et al. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of Clinical Oncology, 23, 3923 3931.